• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume

expresspharmaJuly 01, 2020

Tag: COVID-19 , hydroxychloroquine , MHRA

A global trial designed to find out whether the anti-malaria drug hydroxychloroquine can prevent infection with COVID-19 is to restart after getting approval from the UK medicines agency.

The Medicines and Healthcare Products Regulatory Agency (MHRA) decision on the trial, which is known as the COPCOV trial, comes after the drug was found in another UK trial to have no benefit for patients already infected with COVID-19, the pandemic disease caused by the new coronavirus.


Previous:Linagliptin demonstrates cardiovascular and renal safety in Asian adults with type 2 diabetes

Next:Novartis' Global Innovative siRNA Long-Acting Lipid-lowering Therapy Submitted Clinical Application in China

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

99% up GMP,DMF Hydroxychloroquine sulfate CAS NO.747-36-4

99% up GMP,DMF Hydroxychloroquine sulfate CAS NO.747-36-4
Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
Hydroxychloroquine sulfate

Hydroxychloroquine sulfate
Hydroxychloroquine Sulfate

Hydroxychloroquine Sulfate
SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)

SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)
Hydroxychloroquine EP Impurity C

Hydroxychloroquine EP Impurity C
Hydroxychloroquine Sulfate

Hydroxychloroquine Sulfate
Hydroxychloroquine Impurity 13

Hydroxychloroquine Impurity 13
Hydroxychloroquine sulfate

Hydroxychloroquine sulfate
Hydroxychloroquine EP Impurity D

Hydroxychloroquine EP Impurity D

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service